Related Experiment Video
Updated: May 25, 2026

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation
Published on: August 4, 2023
[Endocrinology]
1Service de médecine interne générale, HUG, 1211 Genève 14. adriana.missana@hcuge.ch
Abstract:
Recent discoveries in molecular biology offer new perspectives in the treatment of endocrine tumors. There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Pasireotide, a new somatostatin analog, demonstrates a strong affinity for somatostatin receptors expressed by corticotroph adenomas. Some recent clinical trials showed a decrease of urinary free cortisol with pasireotide. This new treatment could be useful in case of pituitary surgery failure. Thyroid tumorigenesis involves kinase signaling cascade. Tyrosine-kinase inhibitors have now been tested in the treatment of progressive differentiated iodine refractory thyroid carcinomas or medullary carcinomas and showed modestly encouraging results.
Insights
New molecular biology findings offer novel endocrine tumor treatments. Pasireotide shows promise for Cushing's disease by targeting pituitary adenomas, while tyrosine-kinase inhibitors yield encouraging results for thyroid cancers.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Cushing's disease lacks targeted pituitary adenoma therapies.
- Thyroid cancer progression involves kinase signaling.
- Limited treatment options exist for advanced differentiated thyroid carcinomas and medullary carcinomas.
Purpose of the Study:
- To explore new therapeutic strategies for endocrine tumors based on recent molecular biology discoveries.
- To evaluate the potential of pasireotide in treating Cushing's disease.
- To assess the efficacy of tyrosine-kinase inhibitors in advanced thyroid cancers.
Main Methods:
- Review of recent clinical trials and molecular biology findings.
- Assessment of pasireotide's affinity for somatostatin receptors on corticotroph adenomas.
- Analysis of tyrosine-kinase inhibitors' effects on progressive differentiated iodine-refractory thyroid carcinomas and medullary carcinomas.
Main Results:
- Pasireotide, a somatostatin analog, targets somatostatin receptors on pituitary adenomas relevant to Cushing's disease.
- Clinical trials indicate pasireotide can decrease urinary free cortisol levels.
- Tyrosine-kinase inhibitors have shown modestly encouraging results in treating advanced thyroid carcinomas.
Conclusions:
- Pasireotide represents a potential medical therapy for Cushing's disease, particularly after surgical failure.
- Tyrosine-kinase inhibitors offer a new avenue for managing progressive differentiated and medullary thyroid cancers.
- Advances in molecular biology are driving innovative treatments for endocrine malignancies.
More Related Videos
Related Concept Videos
What is the Endocrine System?
The Endocrine System
Structures of the Endocrine System
An Overview of the Endocrine System
The endocrine system collaborates...
Hormonal Regulation
Hormonal Regulation

